Drugs & Targets Pillar Biosciences, Labcorp collaborate on next-generation sequencing October 15, 2021Vol.47 No.38
Drugs & TargetsFree FDA approves Tecartus for relapsed or refractory B-cell precursor ALL October 08, 2021Vol.47 No.37
Drugs & TargetsFree FDA recognizes MSK database of molecular tumor marker information October 08, 2021Vol.47 No.37
Drugs & TargetsFree EMA validates relatlimab + nivolumab application for advanced melanoma October 08, 2021Vol.47 No.37
Drugs & TargetsFree MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program October 08, 2021Vol.47 No.37
Drugs & TargetsFree NEXT Oncology expands phase I program with VCS partnership October 08, 2021Vol.47 No.37
Drugs & Targets FDA grants 510(k) clearance to Koya Medical’s lymphedema treatment October 01, 2021Vol.47 No.36
Drugs & Targets Novilase breast therapy granted FDA breakthrough designation October 01, 2021Vol.47 No.36
Drugs & Targets Acelarin gets FDA Fast Track designation for treatment of biliary tract cancer October 01, 2021Vol.47 No.36
Drugs & Targets Libtayo sBLA granted FDA priority review in 2L recurrent or metastatic cervical cancer October 01, 2021Vol.47 No.36
